Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Fable Zustovich, Thomas U. Marron et al.|Journal of Hepatology|2023Cited by 62
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Johann von Felden, Giuseppe Cabibbo et al.|Hepatology|2024Cited by 52
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with SorafenibFrancesco Caputo, Andrea Casadei‐Gardini, Vincenzo Dadduzio et al.|PLoS ONE|2020Cited by 47
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B DysfunctionClaudia Angela Maria Fulgenzi, Calogero Cammà, Bernhard Scheiner et al.|JAMA Oncology|2024Cited by 37